# A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

> **NCT01163253** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 2867 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** CP-690,550
- **DRUG:** CP-690,550

## Key facts

- **NCT ID:** NCT01163253
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 2867 (ACTUAL)
- **Last updated:** 2017-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01163253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01163253, "A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01163253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*